Ridogrel enemas in distal ulcerative colitis

Autor: Ouwendijk Rj, Freek J. Zijlstra, van den Ingh Hf, Wilson Jh, Auwerda Jj, Tak Cj
Přispěvatelé: Internal Medicine
Rok vydání: 2001
Předmět:
Zdroj: European Journal of Gastroenterology & Hepatology, 13(4), 397-400. Lippincott Williams & Wilkins
ISSN: 0954-691X
Popis: Objective To evaluate the effect of Ridogrel enemas (Janssen Research Foundation, Beerse, Belgium) on disease activity and mucosal inflammatory mediators in patients with active left-sided ulcerative colitis. Design and methods Eleven patients with active left-sided ulcerative colitis were evaluated in an open non-placebo-controlled pilot study. All patients were treated with Ridogrel enemas (300 mg/40 ml once daily) over four weeks. A disease activity score based on clinical, endoscopic and histological criteria was obtained before and after treatment with Ridogrel. The concentrations of thromboxane B 2 (TxB 2 ), prostaglandin E 2 (PGE 2 ), interleukin-6 (IL-6) and tumour necrosis factor a (TNF-a) were measured in mucosal biopsies before and after treatment. Results One patient discontinued treatment because of progression of disease, the other ten patients tolerated the Ridogrel enemas well. Mucosal TxB 2 concentration decreased significantly in all patients. The mucosal concentrations of the other inflammatory mediators (PGE 2 , IL-6 and TNF-a) were unaltered. The disease score decreased in five patients. However, clinical improvement was not always associated with a decrease in endoscopic and/or histological scores. Conclusions This pilot study shows that Ridogrel enemas selectively reduce mucosal TxB 2 concentration.
Databáze: OpenAIRE